SSK1

CAS No. 2629250-69-5

SSK1( —— )

Catalog No. M34948 CAS No. 2629250-69-5

SSK1 is a compound that selectively kills senescent cells and is a precursor for β-galactosidase, which can reduce the inflammatory response of the body. SSK1 can activate the phosphorylation of p38 MAPK and MKK3/MKK6 in senescent cells, and promote mitochondrial DNA damage in senescent cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 464 In Stock
5MG 353 In Stock
10MG 534 In Stock
25MG 848 In Stock
50MG 1144 In Stock
100MG 1609 In Stock
200MG 2167 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SSK1
  • Note
    Research use only, not for human use.
  • Brief Description
    SSK1 is a compound that selectively kills senescent cells and is a precursor for β-galactosidase, which can reduce the inflammatory response of the body. SSK1 can activate the phosphorylation of p38 MAPK and MKK3/MKK6 in senescent cells, and promote mitochondrial DNA damage in senescent cells.
  • Description
    SSK1, a senescence-specific killing compound, is a β-galactosidase-targeted proagent attenuates inflammation. SSK1 is activated by lysosomal β-galactosidase and selectively killed senescent cells through the activation of p38 MAPK and induction of apoptosis.
  • In Vitro
    Cell Proliferation Assay Cell Line:Primary mouse fibroblasts,Concentration:0.5?μM,Incubation Time:12 hours, 24 hours, 36 hours, 48 hours, 72 hours Result:Both p38 MAPK and MKK3/MKK6 were activated by phosphorylation in senescent cells.
  • In Vivo
    Animal Model:Mice (3-6-month-old) were subjected to transtracheal injection of Bleomycin Dosage:0.5 mg/kg Administration:Intraperitoneally injection; two days every week; for four weeks Result:SSK1 significantly reduced the percentage of SA-β-gal-positive cells in lung by 3.8-fold compared with t hat in vehicle-treated lung-injured mice
  • Synonyms
    ——
  • Pathway
    MAPK/ERK Signaling
  • Target
    p38 MAPK
  • Recptor
    p38 MAPK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2629250-69-5
  • Formula Weight
    788.61
  • Molecular Formula
    C31H34F2N4O18
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 200 mg/mL (253.61 mM; Ultrasonic )
  • SMILES
    [H][C@]1(O[C@H](CO)[C@@H](O)C1(F)F)n1ccc(NC(=O)OCc2ccc(O[C@@H]3O[C@H](COC(C)=O)[C@H](OC(C)=O)[C@H](OC(C)=O)[C@H]3OC(C)=O)c(c2)[N+]([O-])=O)nc1=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Yusheng Cai, et al. Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. Cell Res. 2020 Jul;30(7):574-589.?
molnova catalog
related products
  • UK 383367

    UK-383367 is a procollagen C-proteinase inhibitor with IC50 of 44 nM, has excellent selectivity over MMPs.

  • CC-99677

    CC-99677 (Gamcemetinib) is a selectively targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune diseases that translates biochemical potency into cellular potency as demonstrated by potent inhibition of heat shock protein 27 (HSP1) phosphorylation in LPS-activated monocyte THP-27 cells via a nucleophilic aromatic substitution (SNAr) mechanism.

  • TA-02

    A potent p38 MAPK inhibitor with IC50 of 20 nM.